Illumina (ILMN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business Overview and Market Opportunity

• Next-generation sequencing (NGS) is foundational in biology and clinical applications, generating over 480 petabases of data in 2024, equivalent to five million whole genomes, with a 35% YoY growth in sequencing volume.

• 56% of sequencing consumables revenue comes from clinical customers, with oncology representing 50% of clinical markets.

• NGS is expected to be broadly adopted in healthcare over the next decade, enabling personalized care and deeper insights through multiomics and AI-powered data analysis.

• The total addressable market exceeds $125 billion, but only $10 billion is currently served by NGS, indicating significant growth potential.

• Revenue is highly diversified across products, markets, and geographies, supporting a strong business model and healthy cash flow.

Financial Performance and Outlook

• FY24 revenue reached approximately $4.33B, with Q4 2024 core revenue at ~$1.1B and free cash flow of about $1.07B.

• FY24 non-GAAP operating margin was 21.3%, with Q4 non-GAAP margin at 19.7% and non-GAAP EPS for Q4 in the range of $0.91-$0.93.

• FY25 revenue is expected to be $4.28-$4.4B, with a non-GAAP operating margin of 23% and about 10% non-GAAP EPS growth.

• By 2027, targets include high single-digit growth, 500+ basis points of operating margin expansion, and double-digit to teens EPS growth.

• Share buybacks resumed in 2024, totaling $116 million, with a continued focus on operational excellence and innovation.

Strategic Initiatives, Innovation, and Product Transition

• The NovaSeq X platform is central to growth, with 630 active units, 91 systems placed in Q4, and 75% of high-throughput gigabase volume expected on X by mid-2025.

• NovaSeq X reduced sequencing cost per gigabase from $19.2 to $3.4 and enabled over 460 petabases of high-throughput data sequenced in 2024.

• The MiSeq i100 launched in December, expanding applications and simplifying workflows.

• Constellation mapped read technology enables detection of large structural variants and is set for commercial launch in 2026.

• A new proteomics solution, developed with Standard BioTools, launches in the first half of 2025, offering the largest validated NGS proteomics panel.